New drug cocktail aims to tame metastatic prostate cancer

NCT ID NCT06689163

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called HRS-1167 combined with two standard medications (abiraterone and prednisone) in men with metastatic prostate cancer. The goal is to see if the combination is safe, tolerable, and effective. About 66 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-1167 tablets combined with abiraterone acetate and prednisone
What this could lead to: If successful, this could lead to a new combination treatment option for metastatic prostate cancer that may help control the disease longer.
What could go wrong: This is an early-phase trial with only 66 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China
The First Affiliated Hospital Of Anhui Medical University
RECRUITING

Hefei, Anhui, 230000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.